MedTrace Logo

AutoTransfusion Versus TRAnsfusion in Cancer Surgery

NCT05452538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5808

Last updated 2024-02-26

No results posted yet for this study

Summary

Acute bleeding is one of the most frequent intraoperative adverse events and is burdened with a significant morbidity and mortality rate.

The only available treatment for severe exsanguination is homologous transfusion, but this is itself complicated by side effects.

Nevertheless, systems exist allowing the recovery, treatment and intraoperative reinjection of lost blood, thus limiting transfusions.

Conditions

Interventions

DEVICE

Transfusion

Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05452538 on ClinicalTrials.gov